Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,428 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid-use Disorder
Interventions: Intranasal Oxycodone, Cue Session; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 59 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Manhattan, New York

Conditions: Opioid Use Disorder, Opioid Overdose
Interventions: a bundled intervention, including peer support specialist, buprenorphine, physician care, and telehealth; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Surgery
Interventions: Hydromorphone Hydrochloride; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Pain, Opiate
Interventions: sufentanil; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Buprenorphine, Tramadol, Oral Mucositis (OM) Pain App; Drug · Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pain
Interventions: Fentanyl 400 µg sublingual spray, Actiq® 400 µg transmucosally, Fentanyl citrate injection 100 µg intravenously, Naltrexone 50 mg; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions: Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide); Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 55 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Schizophrenia, Mental Disorders, Alcohol Abuse, Alcoholism, Alcohol-related Disorders
Interventions: Naltrexone or Placebo; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 4
States / cities: Syracuse, New York

Conditions: Lung Tumor
Interventions: IV Acetaminophen, Saline Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Healthy Volunteer, Opioid-use Disorder
Interventions: INDV-2000, Placebo, SUBOXONE® sublingual film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas

Conditions: Head and Neck Squamous Cell Carcinoma, Pain, Stomatitis
Interventions: Gabapentin, Methadone Hydrochloride, Oxycodone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pain, Postoperative
Interventions: Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine; Drug · Other
Lead sponsor: Neumentum, Inc.; Other
Eligibility: 18 Years to 64 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more

Conditions: Back Pain Lower Back Chronic
Interventions: Buprenorphine, Oxycodone Immediate-Release; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 85
States / cities: Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 72 more

Conditions: Diabetic Neuropathies, Herpes Zoster, Neuralgia
Interventions: dextromethorphan; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcohol Drinking
Interventions: Naltrexone and memantine first, Naltrexone and Placebo first; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Rhinoplasty, Non-steroidal Ant Inflammatory Drugs, Opioid Use
Interventions: Norco, NSAID; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Opioid Use Disorder
Interventions: Carfentanil, C-11, Naloxone, Loperamide Hydrochloride; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions: 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Hialeah, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Laparoscopic Colorectal Resection
Interventions: TAP block, Epidural, Paravertebral block, Acetaminophen 1g IV, Dexamethasone 4mg, Midazolam up to 2mg, Propofol 1-2.5 mg/kg, Sevoflurane to keep a bispectral index of between 40-60, Local infiltration with 10 mL of plain ropivacaine 0.25%, Lidocaine, Epinephrine, Hydromorphone; Procedure · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 2006
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alcoholism
Interventions: ondansetron (Zofran), naltrexone (ReVia), Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

Evaluation of Doxazosin to Alter the Abuse of Oxycodone

A Bundled Intervention

Outcomes of Intrathecal Analgesia in Colorectal Surgery

A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)

Buprenorphine Combination Tablet Feasibility - 1

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

Naltrexone Treatment of Alcohol Abuse in Schizophrenia

Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery

Anti-obesity Pharmacotherapy and Inflammation

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Dextromethorphan Versus Placebo for Neuropathic Pain

Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

Narcotics vs NSAIDs for Post-operative Analgesia in Outpatient Rhinoplasty

Multi-System Analysis of Opioid Receptor Binding

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy

Buprenorphine Maintenance for Opioid Addicts - 1

Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)